PSYENCE BIOMEDICAL LTD (PBM)
CA74449F1009 - Common Stock
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable...
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date...
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Get insights into the top gainers and losers of Wednesday's pre-market session.
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence...
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder,...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company...
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Patient screening to be initiated imminently; first subject expected to be randomized into the study in October...
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential...
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
Psyence Biomed to focus on AUD, its second development indication...
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the...
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived...
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a...
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (